Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gynecologic 3Genitourinary 2Thoracic 1Sarcoma 1Plasma cell 1Lymphoid 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Recurrence 1Neoplasms 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 886Rituximab 864Vincristine 382Etoposide 381fludarabine 342Cytarabine 341Doxorubicin 340fludarabine phosphate 319Methotrexate 310Dexamethasone 283Prednisone 282Lenalidomide 245Filgrastim 228Melphalan 200Peripheral Blood Stem Cell Transplantation 184Radiotherapy 175Whole-Body Irradiation 172Busulfan 165Mycophenolic Acid 161venetoclax 158Bendamustine Hydrochloride 158Granulocyte Colony-Stimulating Factor 151Tacrolimus 145ibrutinib 144Bortezomib 138obinutuzumab 125Gemcitabine 113Cyclosporine 110Antilymphocyte Serum 103Carmustine 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × fluoroazomycin arabinoside × Lymphoid × Clear all
NCT04409314 2023-08-21

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy

University of California, San Francisco

Completed
23 enrolled
LymphoidPlasma cell

Multiple Myeloma, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡